Endarterectomy

Vascular Quality Initiative (SVS VQI) Announces the Expansion of Medicare Coverage to Standard Surgical Risk Patients within their TCAR Surveillance Project

Retrieved on: 
Tuesday, June 14, 2022

The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI), a nonprofit organization dedicated to improving the quality of vascular care within hospitals and outpatient facilities, announces that the Centers for Medicare and Medicaid Services (CMS) has expanded coverage for Transcarotid Artery Revascularization (TCAR) to include standard surgical risk patients within the VQI TCAR Surveillance Project.

Key Points: 
  • The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI), a nonprofit organization dedicated to improving the quality of vascular care within hospitals and outpatient facilities, announces that the Centers for Medicare and Medicaid Services (CMS) has expanded coverage for Transcarotid Artery Revascularization (TCAR) to include standard surgical risk patients within the VQI TCAR Surveillance Project.
  • Launched in 2016 by the SVS PSO, the TCAR Surveillance Project uses real-world registry data to evaluate the safety and effectiveness of TCAR against the standard of care, carotid endarterectomy (CEA).
  • The CMS expansion of coverage decision will extend TCAR to standard risk patients in addition to high-risk patients who are currently covered under the TSP.
  • Reimbursement for TCAR within the TCAR Surveillance Project will now apply to Medicare beneficiaries who are deemed to be at high risk and standard risk for adverse events from CEA.

Global Carotid and Renal Artery Stents Markets, 2015-2021 & 2022-2030 Featuring Abbott Labs, Boston Scientific, Cardinal Health, Silk Road Medical, Medtronic, Terumo, Cook, Biotronik - ResearchAndMarkets.com

Retrieved on: 
Friday, March 11, 2022

The "Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Carotid and Renal Artery Stents market for the year 2020 and beyond.
  • Develop business strategies by understanding the trends shaping and driving Carotid and Renal Artery Stents market.

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

Retrieved on: 
Monday, February 28, 2022

TEL AVIV, Israel, Feb. 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, today announced its CGuard Carotid Stent, utilizing its proprietary MicroNet mesh, will be included as a device option for stenting in the CREST-2 Trial. Following the approval of the Carotid Revascularization Endarterectomy or Stenting Trial (CREST-2) Investigational Device Exemption (IDE) supplement application from the U.S. Food and Drug Administration (FDA) last week, InspireMD will be evaluating strategic sites to enable expediated access.

Key Points: 
  • Following the approval of the Carotid Revascularization Endarterectomy or Stenting Trial (CREST-2) Investigational Device Exemption (IDE) supplement application from the U.S. Food and Drug Administration (FDA) last week, InspireMD will be evaluating strategic sites to enable expediated access.
  • The CREST-2 Trial is widely acknowledged as the most significant ongoing trial to scientifically investigate the optimal course of treatment to prevent stokes for asymptomatic patients with significant carotid disease.
  • The trial will enroll an estimated 2,480 participants which will remain in the study for 4 years following the start of intervention.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization

The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or death at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy (CEA).

Key Points: 
  • The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or death at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy (CEA).
  • We believe this indicates that centers that offer TCAR are able to better align patients with the best procedure for their individual clinical and anatomic characteristics.
  • The ENROUTE Transcarotid Stent is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure.
  • The companys flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke.

The Cardiovascular Care Group Leading the Way with New Innovative TCAR Procedure to Treat Carotid Artery Disease

Retrieved on: 
Wednesday, October 28, 2020

SCOTCH PLAINS, N.J., Oct. 28, 2020 /PRNewswire-PRWeb/ -- The Cardiovascular Care Group, in 2017, was the first group in New Jersey to treat carotid artery disease using a new procedure called TransCarotid Artery Revascularization (TCAR).

Key Points: 
  • SCOTCH PLAINS, N.J., Oct. 28, 2020 /PRNewswire-PRWeb/ -- The Cardiovascular Care Group, in 2017, was the first group in New Jersey to treat carotid artery disease using a new procedure called TransCarotid Artery Revascularization (TCAR).
  • TCAR is a clinically proven, minimally invasive and safe approach for high-risk patients who require carotid artery treatment.
  • Carotid artery disease is a form of atherosclerosis, or a buildup of plaque, in the main arteries in the neck that supply oxygen-rich blood to the brain.
  • Prior to TCAR, the main treatment option for severe carotid artery disease was an open surgical procedure called carotid endarterectomy (CEA).

Favorable Outcomes with TCAR vs. Carotid Endarterectomy in Patients with Carotid Artery Disease

Additionally, TCAR patients experience shorter length of hospital stay and are discharged home more often, said Dr. Malas.

Key Points: 
  • Additionally, TCAR patients experience shorter length of hospital stay and are discharged home more often, said Dr. Malas.
  • I am confident that as this compelling clinical evidence continues to mount, TCAR will continue to challenge CEA as the standard of care for treating carotid artery disease in high surgical risk patients.
  • The updated data from the TCAR Surveillance Project evaluated patients between 2016 and 2019, with 8,104 patients receiving TCAR compared to 53,869 patients receiving carotid endarterectomy (CEA), with 6,526 patients in each group analyzed using propensity score matching.
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).

Vascular Patches: Global Markets, 2019 to 2023 with B. Braun Melsungen, Baxter, CryoLife, Getinge, LeMaitre Vascular, and Terumo Leading the Competition - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 13, 2019

The vascular patches market will register a CAGR of close to 5% by 2023.

Key Points: 
  • The vascular patches market will register a CAGR of close to 5% by 2023.
  • The growing older population is expected to drive the growth of the global vascular patches market.
  • Vascular patches are being widely used in the closure of incision site during endarterectomy and vascular reconstruction procedures.
  • Such complications will diminish the long-term efficacy of carotid endarterectomy, thus increasing the need for improvement of vascular patches.

Global Vascular Patch Market by Material, Application and Geography (2018-2023) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 29, 2019

The "Vascular Patch Market - Segmented by Material (Biologic, Synthetic), Application (Carotid Endarterectomy, Open Repair of Abdominal Aortic Aneurysms, Cardiac Aneurysm, Vascular Bypass Surgery) and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Patch Market - Segmented by Material (Biologic, Synthetic), Application (Carotid Endarterectomy, Open Repair of Abdominal Aortic Aneurysms, Cardiac Aneurysm, Vascular Bypass Surgery) and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
  • The vascular patch market is expected to grow at a CAGR of 8.4% over the forecast period.
  • Rapidly growing geriatric population and the subsequent increase in the prevalence of vascular diseases along with increasing adoption of biological patches is driving the market growth.
  • However, the high cost associated with the surgical procedure, changing reimbursement environment and recent product failures and recalls can retard the market growth.

Global Vascular Patches Market Report 2018-2023 - Opportunities in Emerging Markets

Retrieved on: 
Wednesday, July 4, 2018

The "Vascular Patches Market by Material, Application, Patient Care Setting - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Patches Market by Material, Application, Patient Care Setting - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
  • The global vascular patches market is segmented into material, application, end user, and region.
  • Based on application, the vascular patches market is segmented into carotid endarterectomy, open repair of abdominal aortic aneurysms, vascular bypass surgery, and other applications.
  • Based on material, the vascular patches market has been segmented into biologic vascular patch and synthetic vascular patch.

Vascular Patches Market Worth 525.8 Million USD by 2023

Retrieved on: 
Tuesday, June 12, 2018

According to a new market research report "Vascular Patches Market by Material (Biologic, Synthetic), Application (Carotid Endarterectomy, Open Repair of Abdominal Aortic Aneurysms, Vascular Bypass Surgery), Patient Care Setting (Hospitals, Ambulatory Surgical Centers) - Global Forecast to 2023", published by MarketsandMarkets, the market is expected to reach USD 525.8 Million by 2023 from USD 349.6 Million in 2018, at a CAGR of 8.5%.

Key Points: 
  • According to a new market research report "Vascular Patches Market by Material (Biologic, Synthetic), Application (Carotid Endarterectomy, Open Repair of Abdominal Aortic Aneurysms, Vascular Bypass Surgery), Patient Care Setting (Hospitals, Ambulatory Surgical Centers) - Global Forecast to 2023", published by MarketsandMarkets, the market is expected to reach USD 525.8 Million by 2023 from USD 349.6 Million in 2018, at a CAGR of 8.5%.
  • Growth in the Vascular Patches Market is mainly driven by the rapidly growing geriatric population and the subsequent increase in the prevalence of vascular diseases, the increasing number of vascular surgeries performed, and the increasing adoption of biological patches.
  • Based on material, the Vascular Patches Market is segmented into biologic vascular patches and synthetic vascular patches.
  • Of all these product segments, biologic vascular patches accounted for the largest share of the market in 2017.